BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health

MALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that updated policies from BlueCross BlueShield (BCBS) of Michigan and Cambia Health Solutions will broaden access to TMS (transcranial magnetic stimulation) by expanding the eligible age range to 15 years and older. These health policy updates come in response to the Company’s recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS as a first-line add-on treatment for adolescents aged 15-21 with MDD (major depressive disorder).

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024.

“Following quickly after NeuroStar’s FDA clearance for adolescents, these policy updates from major commercial insurance payors represent a crucial step forward in mental healthcare,” stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. “Expanding access to NeuroStar TMS for those aged 15 and older marks significant progress towards ensuring young people receive the care they deserve.”

BCBS of Michigan and Cambia’s Regence BCBS join Premera BCBS with official TMS coverage in the BlueCross BlueShield network for this age group. Premera’s policy covers 2.3 million lives across the states of Washington and Alaska. Neuronetics also recently announced a policy change from Humana to address TMS therapy coverage for adolescents.

Neuronetics is the first and only TMS company with this clearance for the treatment of adolescents and the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.

For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.

About Adolescent Depression
Adolescent depression is a complex and challenging mental health condition that affects young individuals during the crucial period of adolescence. An estimated 4.3 million U.S. adolescents aged 15-21 are affected by MDDi. Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being.

NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of MDD in adolescent patients aged 15-21.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

iWorld Health Organization, Depression Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/depression.

Staff

Recent Posts

Best Supplements For Muscle Growth: Top Legal Bodybuilding Supplements & Anabolic Steroids For Bulking, Cutting & Strength

Backed by Wolfson Brands (UK) Limited, Discover the best supplements for muscle growth, including top…

33 minutes ago

Mitolyn Reviews 2025: Exploring Faux Reviews, Consumer Complaints, & How to Buy Real Mitolyn Purple Peel Exploit!

Mitolyn Mitolyn Seattle, May 03, 2025 (GLOBE NEWSWIRE) -- As more individuals become health-conscious, and…

34 minutes ago

Buy Ibutamoren MK 677 SARMS for Sale Online: MK-677 Before After Results – Where to Order Legal Ibutamoren SARM OTC, Buyers Guide from CrazyBulk

CrazyBulk CrazyBulk New York City, May 03, 2025 (GLOBE NEWSWIRE) -- If you’re serious about…

34 minutes ago

Bioma Review 2025: Revolutionizing Gut Health or Just Another Fad? Honest Analysis Inside By Bioma Probiotic!

Gut transformation through Bioma a perfectly blended combination of probiotics prebiotics and postbiotics Bioma Bioma…

34 minutes ago

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR…

34 minutes ago

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta…

1 day ago